Nephros (NEPH) Competitors

Nephros (NASDAQ:NEPH) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.

Do analysts rate NEPH or PDEX?

Nephros currently has a consensus price target of $5.00, suggesting a potential upside of 29.20%. Pro-Dex has a consensus price target of $56.00, suggesting a potential upside of 41.56%. Given Pro-Dex's higher possible upside, analysts plainly believe Pro-Dex is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pro-Dex	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable valuation and earnings, NEPH or PDEX?

Pro-Dex has higher revenue and earnings than Nephros. Pro-Dex is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$15.52M	2.64	-$1.58M	$0.07	55.29
Pro-Dex	$64.12M	2.01	$2.13M	$2.80	14.13

Do insiders & institutionals believe in NEPH or PDEX?

41.1% of Nephros shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 47.5% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is NEPH or PDEX more profitable?

Pro-Dex has a net margin of 11.06% compared to Nephros' net margin of -6.86%. Pro-Dex's return on equity of 21.68% beat Nephros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	-6.86%	-11.39%	-8.30%
Pro-Dex	11.06%	21.68%	12.40%

Which has more risk & volatility, NEPH or PDEX?

Nephros has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

Does the MarketBeat Community prefer NEPH or PDEX?

Pro-Dex received 144 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 62.06% of users gave Pro-Dex an outperform vote while only 43.33% of users gave Nephros an outperform vote.

Company	Underperform	Outperform
Nephros	Outperform Votes 13 43.33%	Underperform Votes 17 56.67%
Pro-Dex	Outperform Votes 157 62.06%	Underperform Votes 96 37.94%

Does the media prefer NEPH or PDEX?

In the previous week, Nephros and Nephros both had 2 articles in the media. Pro-Dex's average media sentiment score of 0.94 beat Nephros' score of 0.43 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
Nephros	Neutral
Pro-Dex	Positive

Summary

Pro-Dex beats Nephros on 12 of the 15 factors compared between the two stocks.